文献速递骨质疏松与代谢性骨病

罗莫佐单抗治疗重度绝经后骨质疏松:192例女性真实世界数据

Romosozumab in severe postmenopausal osteoporosis-real-world data from 192 women.
PubMed 文献 · Osteoporos Int · 2026-07-08

该研究纳入2020至2024年间192例接受罗莫佐单抗治疗的重度绝经后骨质疏松女性,观察24个月。结果显示腰椎和髋部面积骨密度显著增加,骨形成指标及骨小梁微结构改善,且初治患者骨密度增益显著优于既往接受抗骨吸收治疗者。

要点

  • 罗莫佐单抗可显著提升重度绝经后骨质疏松患者腰椎与髋部骨密度。
  • 初治患者腰椎骨密度增益显著高于既往抗骨吸收治疗者。
  • 治疗6个月后骨形成指标上升,12个月随访骨小梁微结构参数改善。

核心结论

  • 真实世界数据与对照研究结果一致,并提供了微结构变化和生化监测的新见解。

研究设计与样本

  • 单中心真实世界观察性研究,纳入2020至2024年192例接受罗莫佐单抗治疗的重度绝经后骨质疏松女性,观察24个月。

主要发现

  • 腰椎(L1-L4)面积骨密度增加14.47 ± 8.74%(p < 0.001),全髋增加4.15 ± 5.92%(p < 0.001)。
  • 治疗6个月后骨形成参数增加,12个月随访HR-pQCT评估的骨小梁微结构参数增加。
  • 初治患者腰椎面积骨密度变化17.74 ± 8.30%,既往抗骨吸收治疗者10.44 ± 7.67%(p < 0.001)。
  • 上述变化在既往接受骨特异性治疗的患者中显著更低。

临床怎么用

  • 罗莫佐单抗可用于重度绝经后骨质疏松,尤其初治患者骨密度增益更显著。
  • 治疗中可结合骨形成标志物和HR-pQCT微结构评估序贯治疗效应。

局限性

  • 真实世界数据仍有限,需更大样本和更长观察时间评估序贯治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Romosozumab, used to treat severe osteoporosis, still lacks real-world treatment data. We observed significant gains in spinal and hip bone mineral density, as well as improvements in trabecular microarchitecture. These real-world observations corroborate controlled trials and provide new insights into sequential therapy effects and the management of severe osteoporosis. PURPOSE: Osteoporosis is a common disease that leads to fractures causing immobility and pain. Pharmacological therapy plays a pivotal role in osteoporosis management with a growing number of approved drugs. Romosozumab, an anti-sclerostin antibody, is approved in several countries for the treatment of severe osteoporosis in postmenopausal women. Clinical trials have demonstrated significant gain of areal bone mineral density (aBMD) in these patients over 12 months of treatment; however, real-world data is still limited. METHODS: From 2020 to 2024, 192 postmenopausal women with severe osteoporosis treated with romosozumab were identified at our institution. Clinical data from a 24-month observation period were analyzed, comprising aBMD by dual-energy X-ray absorptiometry (DXA), bone microstructure by high-resolution peripheral quantitative computed tomography (HR-pQCT), and biochemical bone turnover markers. RESULTS: Patients treated with romosozumab showed significant gains in spinal (L1-L4) and hip aBMD (lumbar spine: 14.47 ± 8.74%, p < 0.001; total hip: 4.15 ± 5.92%, p < 0.001), accompanied by an increase in bone formation parameters after 6 months and an increase in trabecular microarchitectural parameters assessed by HR-pQCT in 12-month follow-up. These changes were significantly lower in patients with previous bone specific treatment. Treatment-naïve (TN) patients benefited significantly more than those previously treated with antiresorptive (AR) medication (lumbar spine aBMD change: TN: 17.74 ± 8.30%, AR: 10.44 ± 7.67%, p < 0.001). This was supported by the dependency of aBMD gain on baseline bone formation markers. CONCLUSION: Our real-world data corroborate the results from controlled studies and provide new insights into microstructural changes as well as biochemical treatment monitoring. To fully evaluate sequential therapy, larger studies and longer observation times are needed in the future.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Dehne N, von Brackel FN, Günzl C, et al. Romosozumab in severe postmenopausal osteoporosis-real-world data from 192 women. Osteoporos Int. 2026. PMID: 42417976. doi:10.1007/s00198-026-08127-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。